A Study of the Effects of Abnormal Steroid Metabolome on Bone Strength and Quality, Bone Density, Bone Remodeling, and Body Composition in Patients with MACS and Healthy Volunteers


About this study

The purpose of this study is to determine the effect of abnormal steroid metabolome on bone strength and quality, bone density, bone remodeling, and body composition in patients with mild autonomous cortisol secretion (MACS) and healthy volunteers.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 50 or older.
  • Willing to have bone density, quality and strength, bone turnover markers, as well as body composition measurements.

Exclusion Criteria:

  • Exogenous steroids therapy within the last 5 years.
  • Steroid hormone replacement therapy ( for adrenal insufficiency, hypogonadism, menopause).
  • Therapy for osteoporosis.
  • Any drug therapy affecting bone metabolism.
  • Comorbidities affecting steroid metabolome or bone metabolism.
  • Recent fracture.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Irina Bancos, M.D.

Open for enrollment

Contact information:

Melinda Thomas B.S.


More information


Publications are currently not available

Mayo Clinic Footer